Pay in 4 interest-free payments of $6.29 Learn more
Ships within 48 hours · Estimated delivery Oct 22 - Oct 27
Some patients also ask about stretching a prescription with lower doses, which saves money but has no trial support
Lee, P., Greenfield, J
J Control Release 273:2129 Brayden DJ, Maher S (2021) Transient permeation enhancer (TPE) technology for oral delivery of octreotide: a technological evaluation
In addition to Wegovy and Zepbound, Shed offers compounded semaglutide and compounded tirzepatide, which are not FDA approved but cost only $199+
If any apply, the medication should not be prescribed: Personal or family history of medullary thyroid carcinoma (MTC) Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) Known serious hypersensitivity to the active medication or to a related incretin-receptor agonist Clinical precautions that prompt careful screening These are not absolute contraindications on the FDA label, but they meaningfully change the risk-benefit conversation
